Charles Sternberg, Associate Editor08.02.23
Earlier this year, CooperCompanies signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, for approximately $875 million, however things don’t always go as planned. According to a recent statement from the Federal Trade Commission (FTC), the acquisition has been terminated.
In a statement, the FTC, which is responsible for protecting consumers and promoting competition (among other things), said it had concerns about how the deal would impact reproductive health markets.
FTC Bureau of Competition Director Holly Vedova explained:
“Following a full-phase investigation by FTC staff, CooperCompanies’ decision to abandon this proposed acquisition ensures that critical reproductive health markets remain competitive. The FTC is committed to protecting patients from higher costs and preserving the incentive to innovate. This deal termination protects competition and is a win for patients.”
Read the full FTC statement.
In a statement, the FTC, which is responsible for protecting consumers and promoting competition (among other things), said it had concerns about how the deal would impact reproductive health markets.
FTC Bureau of Competition Director Holly Vedova explained:
“Following a full-phase investigation by FTC staff, CooperCompanies’ decision to abandon this proposed acquisition ensures that critical reproductive health markets remain competitive. The FTC is committed to protecting patients from higher costs and preserving the incentive to innovate. This deal termination protects competition and is a win for patients.”
Read the full FTC statement.